Who Paid My Doc
Shobha Swaminathan
Infectious Disease Newark, NJ Medical Doctor
NPI 1275564411 CMS profile 57207
140 Bergen St, Acc Level D, Newark, NJ 07103
General payments
$60,322
Research payments
$1,633
Ownership & investment interest
$0
Research they led as principal investigator
$1,326,265
Through program year 2025, Shobha Swaminathan of Newark, NJ is reported in the CMS Open Payments database as having received $60,322 across 31 general payments and $1,633 in research payments paid to them. Separately, studies naming them as principal investigator received $1,326,265 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $88 | 1 | |
| 2024 | Research | $383 | 2 | |
| 2023 | General | $5,358 | 3 | |
| 2022 | General | $3,954 | 6 | |
| 2021 | General | $7,050 | 5 | |
| 2020 | General | $13,988 | 3 | |
| 2019 | General | $29,883 | 13 | |
| 2019 | Research | $1,249 | 9 |
Beside peers
- Shobha Swaminathan
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Shobha Swaminathan were reported at $88. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Shobha Swaminathan | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $29,883 | $190 | $60–$862 | $163 |
| 2020 | $13,988 | $124 | $32–$606 | $114 |
| 2021 | $7,050 | $148 | $38–$905 | $132 |
| 2022 | $3,954 | $166 | $50–$834 | $149 |
| 2023 | $5,358 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $88 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 60 drugsPart D claims
2,153
Drug cost
$2,208,108
Branded share of claims
41.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 201 | $807,716 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 82 | $370,950 | |
| Tivicay Dolutegravir Sodium | Brand | 101 | $257,032 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 58 | $203,024 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 46 | $156,947 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 21 | $81,167 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 19 | $63,675 | |
| Cabenuva Cabotegravir/Rilpivirine | Brand | 12 | $51,086 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 17 | $37,526 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 11 | $31,782 |
The 10 drugs with the highest cost, of 60 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 10 billing codesPaid by Medicare
$4,979
Medicare patients
38
Services billed
69
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 58% | |
| Chronic kidney disease | 50% | |
| Depression | 47% | |
| Arthritis | 47% | |
| COPD | 39% | |
| Heart failure | 34% | |
| Ischemic heart disease | 34% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
42 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in New Jersey
Keith Gottesdiener
Infectious Disease · Rahway, NJ
Jihad Slim
Infectious Disease · Newark, NJ
Maria Szabela
Infectious Disease · Newark, NJ
Ronald Nahass
Infectious Disease · Hillsborough, NJ
Christopher Lucasti
Infectious Disease · Somers Point, NJ
Spartaco Bellomo
Infectious Disease · Jersey City, NJ
Related records
Infectious Disease in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.